Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/Ritonavir in HIV-1-Infected, Treatment-Naive ARTEMIS Patients at Week 96

Autor: Fourie, J, Flamm, J, Rodriguez-French, A, Kilby, D, Domingo, P, Lazzarin, A, Ballesteros, J, Sosa, N, Van De Casteele, T, DeMasi, R, Spinosa-Guzman, S, Layreys, L

Publikováno v: HIV CLINICAL TRIALS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Objectives: ARTEMIS demonstrated significantly greater efficacy of once-daily darunavir/ritonavir (DRV/r) 800/100 mg versus lopinavir/ritonavir 800/200 mg (total daily dose) in treatment-naive, HIV-1-infected patients at week 96. The influence of bas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::33950330eb000f28fabae6461076adeb
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12075